

Scientific Letter**High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles****Keywords:** TDT; NTD; Antiphospholipid antibody; Pediatrics.**Published:** November 1, 2020**Received:** June 8, 2020**Accepted:** October 3, 2020**Citation:** Chinsuwan J, Klaihmon P., Kadegasem P., Chuansumrit A., Soisamrong A., Pattanapanyasat K., Wongwerawattanakoon P., Sirachainan N. High prevalence of antiphospholipid antibodies in children with non-transfusion dependent thalassemia and possible correlations with microparticles. *Mediterr J Hematol Infect Dis* 2020, 12(1): e2020071, DOI: <http://dx.doi.org/10.4084/MJHID.2020.071>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the editor.

Thromboembolism (TE) is one of the complications of thalassemia disease. The incidences have been reported about 0.9-4.0% in TDT and 3.9-29.0% in NTD. TE's etiologies in thalassemia are an abnormal expression of PS, platelet and endothelial activations, decreased nitric oxide, and splenectomy.⁴ In addition, MPs from red blood cells (RBCs), platelets, endothelium, and leucocytes increase in thalassemia diseases and play a role in TE development.⁵⁻⁷ The exposure of PS in thalassemia may contribute to the occurrence of APAs. For example, β 2GPI, a glycoprotein in circulation, when attaching to PS, undergoes a structural change that could induce antibody formation.⁸ The prevalence of APAs in thalassemia has been reported mostly in β thalassemia patients with the incidence rates of 42.7% of aCL-IgG⁹, 16.0% of lupus anticoagulant (LA), 30.0% of aCL-IgM, and 6.0% of aCL-IgG.¹⁰ Currently, there are limited studies on APAs in NTD. In addition, the etiology of APAs in thalassemia is still unknown. We report the positive rates of APAs in TDT and NTD children and demonstrate the association of APAs with RBC, platelet, endothelial, and leucocyte MPs.

Patients with thalassemia disease and healthy controls who had normal hemoglobin (Hb) and Hb typing were enrolled. After obtaining written consent from parents and patients, blood was drawn for APAs – including LA (Dade Behring Siemens Healthcare GmbH, Germany), aCL and α 2GPI antibodies (both IgG and IgM) (EUROIMMUN Medizinische Labordiagnostika AG, Germany), and MPs of RBC, platelet, leukocyte, and endothelium by flow cytometry.⁶ The cut-off levels were defined as >99th percentile for aCL-IgM, aCL-IgG, α 2GPI-IgM, and α 2GPI-IgG. Positive APA was determined by the subjects having at least one positive test result of one of the APA types according to the Sydney criteria.¹¹

A total of 161 subjects were divided into three

groups: 55 subjects with TDT, 44 subjects with NTD, and 62 controls. TDT subjects had received regular RBC transfusions (every 3-4 weeks) to maintain a pre-transfusion mean \pm SD of Hb at 9.0 \pm 1.2 g/dL. After receiving RBC transfusion, their mean Hb level was 12.3 g/dL. They required mean \pm SD RBC transfusions of around 145.0 \pm 49.3 ml/kg/year. NTD group who required only occasional RBC transfusion of around 4.0 \pm 11.7 ml/kg/year. As a result of regular RBC transfusion, the Hb levels in TDT and NTD subjects in the study were similar, with higher mean corpuscular volume present in TDT than in NTD subjects (**Table 1**).

The positive APA rate in all thalassemia patients as a group (23.0%) was higher than in controls (17.9%). The positive APA rate was highest in NTD subjects (29.5%), and similar levels were shown between TDT (18.2%) and control groups (17.9%), although no significant differences were demonstrated. The LA test was positive in 14.5% of TDT subjects, 20.5% of NTD subjects, and 12.8% of controls. When using the level cut-off of the 99th percentile in controls to determine the positivity of aCL (IgM = 9.99 U/mL; IgG = 8.46 U/mL) and α 2-GPI (IgM = 23.45 U/mL, IgG = 3.44 U/mL) respectively, the aCL-IgM test was positive in 1.8% of TDT subjects and 1.6% of controls. The aCL-IgG test was positive in 4.5% of NTD subjects and 3.2% of controls. The α 2GPI-IgM and α 2GPI-IgG were positive in 1.8% and 5.4% respectively in TDT subjects, 4.5%, and 11.4% in NTD subjects, and 1.6% for both IgM and IgG in controls. The prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT) values in thalassemia subjects, when compared to the values in controls, can be attributed to the patients with positive APAs present in the thalassemia groups, as the APTT and PT values were higher in thalassemia patients who had positive APA when compared to negative APA. It is noted that a significant difference was demonstrated only in PT values (34.1 \pm 4.2 vs. 30.9 \pm 3.7

Table 1. Demographic data and laboratory parameters of transfusion-dependent thalassemia (TDT) subjects, non-transfusion-dependent thalassemia (NTDT) subjects, and controls.

Parameter	TDT (N=55)	NTDT (N=44)	Controls (N=62)	P- value	P- value TDT-NTDT	P- value TDT-control	P- value NTDT-control
Age (yr)*	11.6 ± 4.5	13.4 ± 4.9	13.5 ± 3.7	0.033	0.568	0.003	0.002
Female:male (%)	38:62	37:63	39:61	0.969	0.853	0.953	0.806
Diagnosis							
- HbE/β	49 (89.1%)	4 (9.1%)					
- β major	3 (5.5%)	-					
- HbH/CS	2 (3.6%)	12 (27.3%)					
- AE Barts'/CS	1 (1.8%)	1 (2.3%)					
- AE Barts'	-	1 (2.3%)					
- HbH	-	26 (59.1%)					
RBC transfusion rate (ml/kg/yr)*	145 ± 49.3	4 ± 11.7	-	<0.001	-	-	-
Hb (g/dL)*	9.0 ± 1.2	9.2 ± 1.2	13.6 ± 1.6	<0.001	0.478	0.101	0.046
MCV (fL)*	71.1 ± 6.6	60.9 ± 7.9	81.3 ± 8.0	<0.001	0.051	0.487	0.304
MCH (pg)*	22.7 ± 2.7	17.3 ± 2.3	26.5 ± 3.1	<0.001	0.356	0.460	0.132
MCHC (g/dL)*	31.9 ± 1.6	28.7 ± 2.0	32.6 ± 1.1	<0.001	0.943	0.002	0.043
Platelet (x 10 ³ /mL)*	352.6 ± 167.5	338.9 ± 96.1	317.9 ± 80.5	0.296	0.068	0.003	0.153
CRP (mg/L) [#]	1 (1-24.5)	1 (1-8.7)	1 (1-10.3)†	0.637	0.320	0.841	0.470
Ferritin (ng/mL) [#]	1,429.2 (294.1-6,081.0)	103.9 (15.7-1,493.7)	-	<0.001	-	-	-
PT (sec)*	14.2 ± 1.2	13.6 ± 0.9	12.8 ± 0.6†	<0.001	0.303	0.003	0.012
INR*	1.2 ± 0.1	1.4 ± 1.5	1.1 ± 0.1†	0.314	0.060	0.003	0.088
APTT (sec)*	34.8 ± 4.5	32.6 ± 3.5	30.7 ± 3.5†	<0.001	0.026	0.010	0.517
TT (sec)*	11.1 ± 0.5	11.3 ± 0.5	11.1 ± 0.6†	0.141	0.148	0.586	0.541
aCL-IgM [#]	2.0 (2.0-11.0)	2.0 (2.0-4.7)	2.0 (0.4-10.0)	0.355	0.534	0.010	0.007
aCL-IgG [#]	2.0 (2.0-8.1)	2.0 (2.0-100.2)	2.0 (0.4-8.5)	0.106	0.188	0.037	0.006
Antiβ2-GPI-IgM [#]	3.8 (2.0-80.3)	2.8 (2.0-33.0)	4.2 (1.3-23.5)	0.637	0.083	0.730	0.048
Antiβ2-GPI-IgG [#]	2.0 (2.0-10.3)	2.0 (2.0-183.8)	2.0 (2.0-3.4)	0.165	0.124	0.373	0.015

* mean ± SD, [#] median (range), [†] controls n=39, APTT, activated partial thromboplastin time; CRP, C - reactive protein; CS, Constant Spring; Hb, haemoglobin; INR, international normalized ratio; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; PT, prothrombin time; RBC, red blood cell; TT, thrombin time. Genetic of thalassemia: α^{CS}; HBA2 c.427T>C, β^E; HBB:c.79G>C, AE Barts'/CS; --/α^{CS}α / β^E/β, HbH/CS; --/α^{CS}α

sec, $P=0.57$, 14.2 ± 1.2 vs. 12.8 ± 0.7 sec, $P=0.003$ respectively).

Percentages of RBC, platelet, endothelial, and leucocyte MPs in the TDT and NTDT groups were significantly higher than those in the controls (Table 2). There were no significant differences in MPs percentages between the TDT and NTDT groups except

for platelet MPs, which were significantly higher in TDT subjects than NTDT subjects (Table 2). β 2GPI-IgG level significantly correlated with leucocyte (CD11b) MPs. ACL-IgM level significantly correlated with endothelial (CD31) MPs (Table 3).

Previous studies have reported a positive rate of LA in β thalassemia of 1.5-16.0%, aCL-IgG of 13.0-42.7%,

Table 2. Percent red blood cell; RBC (Glycophorin A; GPA), platelet (CD41), endothelium (CD31, 144) and white blood cell (CD11b, CD45) microparticles (MPs) in transfusion-dependent thalassemia (TDT) subjects, non-transfusion-dependent thalassemia (NTDT) subjects, and controls.

Percents of MPs (/microL)	TDT (n=55)		NTDT (n=44)		Control (n=39)		p-value ANOVA	p-value (post hoc LSD)		
	Mean ± SE	Mean adjusted ± SE	Mean ± SE	Mean adjusted ± SE	Mean ± SE	Mean adjusted ± SE		TDT vs NTDT	TDT vs Control	NTDT vs Control
GPA	42.8 ± 3.1	43.5 ± 2.9 [#]	37.1 ± 2.7	36.9 ± 3.8 [#]	1.7 ± 0.5	1.0 ± 4.6 [#]	<0.001*	0.182	<0.001*	<0.001*
CD41	28.0 ± 1.9	28.2 ± 1.6 [£]	21.0 ± 2.0	21.1 ± 1.8 [£]	1.0 ± 0.2	0.6 ± 1.2 [£]	<0.001*	0.004*	<0.001*	<0.001*
CD31	26.0 ± 2.0	25.3 ± 2.2 [#]	20.3 ± 2.4	21.2 ± 2.9	1.0 ± 0.2	0.9 ± 3.4 [#]	<0.001*	0.267	<0.001*	<0.001*
CD144	19.9 ± 1.9	18.6 ± 1.9 [#]	18.3 ± 2.0	20.3 ± 2.5	0.9 ± 0.3	0.5 ± 3.0 [#]	<0.001*	0.597	<0.001*	<0.001*
CD11b	1.1 ± 0.2	1.0 ± 0.2 [¥]	1.2 ± 0.2	1.2 ± 0.2 [¥]	0.3 ± 0.1	0.3 ± 0.2 [¥]	0.006*	0.442	0.013*	0.002*
CD45	6.1 ± 0.8	6.2 ± 0.8 [¥]	6.1 ± 1.1	6.2 ± 0.9 [¥]	0.8 ± 0.1	0.6 ± 0.9 [¥]	<0.001	0.99	<0.001*	<0.001

[#]After adjusted by RBC, Hb and age, [¥]adjusted by WBC, age and gender, [£]adjusted by platelet, age and gender.

Table 3. Correlation between antiphospholipid antibodies and percentages of microparticles.

Antiphospholipid antibodies	GPA MPs		CD41 MPs		CD31 MPs		CD144 MPs		CD11b MPs		CD45 MPs	
	r	p-value	r	p-value	r	p-value	r	p-value	r	p-value	r	p-value
Lupus anticoagulant (ratio)	-0.138	0.107	-0.112	0.190	0.055	0.524	-0.083	0.334	-0.051	0.554	-0.011	0.899
Anticardiolipin-IgM (U/mL)	0.057	0.508	0.115	0.177	0.178	0.037*	0.128	0.135	-0.141	0.100	0.135	0.115
Anticardiolipin-IgG (U/mL)	-0.046	0.592	-0.119	0.165	-0.087	0.309	-0.027	0.753	0.099	0.248	-0.019	0.821
Anti β 2GPI-IgM (U/mL)	0.011	0.899	0.005	0.950	-0.062	0.469	0.036	0.675	-0.068	0.428	-0.006	0.941
Anti β 2GPI-IgG (U/mL)	0.131	0.125	0.059	0.491	0.086	0.315	0.118	0.167	0.200	0.019*	0.100	0.244

P-value by Spearman's rho Correlations

and aCL-IgM of 6.0%.^{9,10,12} Our study demonstrated that subjects with positive LA in the TDT group consisted of 14.5% and aCL-IgM of 1.8%. The differences between the positivity rates in APAs may be due to several factors, including the diversity of the population among the studies, the disease severity, treatment plan (e.g., regular RBC transfusions), antibody detection methods, and differences in cut-off value for positivity. The other types of APAs – β 2GPI-IgM and IgG – were also included in the present study but did not feature any previous studies.^{9,10,12} The rates of positive β 2GPI-IgM and IgG in the TDT group were 1.8% and 5.4%, respectively, which were higher than the aCL-IgM and IgG positivity rates. In the NTDT group, the rates of all positive APAs (29.5%) were higher than those in the TDT group (18.1%), although there was no statistically significant difference demonstrated. Higher APA positivity rates in NTDT subjects were also found for individual antibodies, including LA, aCL-IgG, β 2GPI-IgM, and IgG antibodies. To our knowledge, there have been very few studies that have reported on positive APAs in NTDT subjects, particularly in children.

MPs were higher in the TDT and NTDT groups when compared to those levels in controls. All MPs levels (except for platelet MPs) between TDT and NTDT groups were not significantly different. The similar MPs levels in TDT subjects, despite more severe symptoms, may be related to the regular RBC transfusions received by TDT subjects, and that can reduce the amount of abnormal PS surfaces exposed. This hypothesis is supported by a study by Atichartakarn *et al.*¹³ The study enrolled severe splenectomized thalassemia with pulmonary hypertension subjects. After receiving RBC transfusions, the amount of PS surface exposing RBC was reduced in those subjects. The report suggested that the reduction of erythropoiesis and PS exposing cells' dilution was due to RBC transfusion.¹³ In addition, platelet activation was reduced after regular RBC transfusion.

Our study also demonstrated statistically significant correlations between β 2GPI-IgG and leucocyte (CD11b) MPs and aCL-IgM level and endothelial (CD31) MPs, although the correlations were not strong. These findings point to the likelihood that APAs in

thalassemia subjects may be related to PS's expression. The sites of PS expressed surfaces are where glycoproteins, such as β 2GPI, bind to anionic PS surfaces. After binding to PS surfaces, β 2GPI changes the conformation of the molecule and induces antibody formation.⁸ Even stronger correlations may be demonstrated in older subject age groups because the antibody formation may require time after exposure to the PS expressed apoptotic cells.¹⁴ In this study, the lower positive APA rate in the TDT group compared to the NTDT group may be related to the regular RBC transfusion, which may reduce the exposure to PS expressed MPs, especially early after transfusion. In addition to regular RBC transfusions, deferiprone has been reported to improve immunological response, possibly from the iron chelator's direct action and the reduction of free iron radicals.¹⁵ All TDT patients in the present study received iron chelation, which was started when serum ferritin levels reached more than 1,000 ng/mL. Deferiprone was the most prescribed medication in the present study, accounting for 76.4% of TDT subjects. The strengths of the present study were that it demonstrated a high prevalence rate of APAs, especially in thalassemia patients who received an occasional transfusion, and to our knowledge, the correlations of APAs to MPs was first demonstrated.

In summary, high APA positive rates, associated with high MPs, were demonstrated in a pediatric population with thalassemia disease, especially NTDT. This suggests that MPs may play a role in APA development. Further larger cohort and basic research studies are required to confirm these results, better understand the occurrence of APAs in this population, and demonstrate the risk of TE-linked APA presence in thalassemia subjects.

Acknowledgements. The authors would like to thank all physicians and paramedical personnel who have been involved in treating these patients. JC performed the research and wrote the manuscript, PK, AS and KP performed laboratory study, AC and PW took care of the patients, and NS designed the study, took care of the patients, and wrote the manuscript. NS is a recipient of the Career Development Award from the Faculty of

Jitlada Chinsuwan¹, Phatchanat Klaihmon², Praguaywan Kadegasem¹, Ampaiwan Chuansumrit¹, Anucha Soisamrong³, Kovit Pattanapanyasat², Pakawan Wongwerawattanakoon⁴ and Nongnuch Sirachainan^{1*}.

¹ Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

² Center of Excellence for Flow Cytometry, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

³ Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

⁴ Division of Pediatric Nursing, Nursing Department, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Competing interests: The authors declare no conflict of Interest.

Correspondence to: Prof. Nongnuch Sirachainan, MD. Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Phayathai, Rajathewi district, Bangkok 10400, Thailand. Tel: +66 2 201 1749; Fax: +66 2 201 1748. E-mail: nongnuch.sir@mahidol.ac.th

References:

1. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. *Haematologica*. 2013;98(6):833-44. <https://doi.org/10.3324/haematol.2012.066845> PMID: 23729725
2. Logothetis J CM, Economidou J, Stefanis C, Hakas P, Augoustaki O, Sofroniadou K, et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. *Neurology*. 1972;22(3):294-304. <https://doi.org/10.1212/wnl.22.3.294> PMID: 5062264
3. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. *Br J Haematol*. 2000;111(2):467-473. <https://doi.org/10.1046/j.1365-2141.2000.02376.x> PMID: 11122086
4. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood*. 2002;99(1):36-43. <https://doi.org/10.1182/blood.v99.1.36> PMID: 11756150
5. Kheansaard W, Phongpao K, Paiboonsukwong K, Pattanapanyasat K, Chaichompoo P, Svasti S. Microparticles from β -thalassaemia/HbE patients induce endothelial cell dysfunction. *Sci Rep*. 2018;8(1):13033. <https://doi.org/10.1038/s41598-018-31386-6> PMID: 30158562 PMCID: PMC6115342
6. Klaihmon P, Vimonpatranon S, Nulsri E, Lertthammakiat S, Anurathapan U, Sirachainan N et al. Normalized levels of red blood cells expressing phosphatidylserine, their microparticles, and activated platelets in young patients with β -thalassaemia following bone marrow transplantation. *Ann Hematol*. 2017;96(10):1741-1747. <https://doi.org/10.1007/s00277-017-3070-2> PMID: 28748286
7. Youssry I, Soliman N, Ghamrawy M, Samy RM, Nasr A, Abdel Mohsen M. Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients. *Ann Hematol*. 2017;96:597-603. <https://doi.org/10.1007/s00277-017-2925-x> PMID: 28168351
8. Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. *Blood Rev*. 2008;22(2):93-105. <https://doi.org/10.1016/j.blre.2007.09.001> PMID: 17964017
9. Kashef S, Karimi M, Amirghofran Z, Ayatollahi M, Pasalar M, Ghaedian MM, et al. Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. *Int J Lab Hematol*. 2008;30(1):11-16. <https://doi.org/10.1111/j.1751-553X.2007.00916.x> PMID: 18190462
10. Sharma S, Raina V, Chandra J, Narayan S. Lupus anticoagulant and anticardiolipin antibodies in polytransfused betathalassemia major. *Hematology*. 2006;11(4):287-290. <https://doi.org/10.1080/10245330600954130> PMID: 17178669
11. Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor pro-thrombotic activity. *Curr Opin Hematol*. 2019;119(6):860-870. <https://doi.org/10.1055/s-0039-1681102> PMID: 30861549
12. Giordano P, Galli M, Del Vecchio GC, Altomare M, Norbis F, Ruggeri L. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. *Br J Haematol*. 1998;102(4):903-906. <https://doi.org/10.1046/j.1365-2141.1998.00853.x> PMID: 9734637
13. Atichartakarn V, Chuncharunee S, Chandanamatttha P, Likittanasombat K, Aryrachai K. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/ β -thalassaemia patient. *Blood*. 2004;103(7):2844-2846. <https://doi.org/10.1182/blood-2003-09-3094> PMID: 14645000
14. Pittoni V, Isenberg D. Apoptosis and antiphospholipid antibodies. *Semin Arthritis Rheum*. 1998;28(3):163-178. [https://doi.org/10.1016/s0049-0172\(98\)80033-4](https://doi.org/10.1016/s0049-0172(98)80033-4) PMID: 9872477
15. Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D. Effects of deferoxamine on immune status and cytokine pattern in thalassaemia major. *Acta Haematol*. 2002;108(3):144-149. <https://doi.org/10.1159/000064705> PMID: 12373086